Mixture-Design Optimization of an Intranasal Self-Nanoemulsifying Drug Delivery System Co-Loaded with Olmesartan Medoxomil and Apigenin: Composition Modeling and Ex Vivo Nasal Permeation
Background/Objectives: Ischemic brain injury involves parallel oxidative, inflammatory, and vascular cascades. Olmesartan medoxomil and apigenin act on complementary arms and can serve this purpose. This study developed a self-nanoemulsifying drug delivery system (SNEDDS) co-loaded with both agents for intranasal use. Constrained mixture design was used to determine its actual composition. Methods: Oil and cosolvent were selected by saturation solubility and surfactant by emulsification transmittance. The proportions of Kolliphor EL (40–70% w/w), poly(ethylene glycol) 400 (5–30% w/w), and Imwitor 308 (20–40% w/w) were treated as mixture variables and each drug’s solubility as the response. Desirability analysis identified the optimum composition, which was experimentally verified. After that, it was compared with a drug suspension for permeation across excised goat nasal mucosa in Franz diffusion cells. Results: Apigenin solubility followed a linear mixture model and olmesartan medoxomil a quadratic model. The optimum composition (52.33% Kolliphor EL, 27.67% poly(ethylene glycol) 400, 20.00% Imwitor 308) gave observed solubilities of 11.82 and 6.91 mg/g, within the 95% prediction intervals. Steady-state flux rose from 0.85 ± 0.68 to 8.46 ± 2.51 µg/cm2/h for olmesartan medoxomil and from 0.18 ± 0.17 to 10.06 ± 3.63 µg/cm2/h for apigenin. Conclusions: A constrained mixture design identified a SNEDDS composition that accommodated both drugs and markedly increased their transport across excised nasal mucosa relative to a suspension. These findings establish a formulation basis for the intranasal administration of this drug combination.
Authors
- Mohamed M. Badran (ORCID: https://orcid.org/0000-0003-1814-0215)
- Ehab Mostafa Elzayat (ORCID: https://orcid.org/0000-0001-5177-4477)
- Abdelrahman Y. Sherif (ORCID: https://orcid.org/0000-0003-1842-6010)
- Mohammad A. Altamimi (ORCID: https://orcid.org/0000-0003-4877-864X)
- Sultan Almutairy
Institutions
- King Saud University (SA)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3390/pharmaceutics18111487
- Primary Topic
- Advanced Drug Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- King Saud University